Apparent Mineralocorticoid Excess (AME) Syndrome

Apparent mineralocorticoid excess (AME) is a rare, usually childhood-onset condition where the body acts as if it has too much aldosterone (the salt-retaining hormone) even though aldosterone itself is low. The problem is not the aldosterone hormone; it’s an enzyme in the kidney called 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). This enzyme normally changes cortisol (which is plentiful) into cortisone (which is inactive at the mineralocorticoid receptor). When the enzyme does not work well, ordinary cortisol floods the mineralocorticoid receptor, “mimicking” aldosterone. The result is salt and water retention, high blood pressure, low potassium, and metabolic alkalosis with low renin and low aldosterone—hence the term pseudohyperaldosteronism. Most cases are inherited due to HSD11B2 gene mutations; some are acquired (for example, from licorice). PubMed+2PubMed+2

AME is a genetic kidney-salt problem where your body’s own cortisol acts like aldosterone because the kidney enzyme that should “turn cortisol off” is weak or missing. The result is too much salt kept in the body, not enough potassium, and high blood pressure that often starts in childhood. Blood tests show low renin and low aldosterone, which is unusual in typical salt-driven high blood pressure. A special urine steroid test shows too much cortisol compared with cortisone. Genetic testing finds changes in HSD11B2. PubMed Central+1

Other names

AME is also called 11β-HSD2 deficiency, Ulick syndrome, and a form of pseudohyperaldosteronism. All these names point to the same core idea: cortisol is not properly inactivated in the kidney, so it drives the mineralocorticoid receptor and causes low-renin hypertension. Wikipedia+1

Types

1) Classic (severe, early-onset) AME. Infants or young children present with very high blood pressure, failure to thrive, marked hypokalemia, and very high urine cortisol-to-cortisone metabolite ratios. This usually reflects two pathogenic HSD11B2 variants (autosomal recessive). PubMed

2) Non-classic (partial, later-onset) AME. Some individuals have milder or later-onset disease due to partial loss of 11β-HSD2 activity; they still show low renin/low aldosterone, but features may be subtler. AHA Journals

3) Acquired AME-like state (licorice/drug-induced). Ingestion of glycyrrhizin/glycyrrhetinic acid from natural licorice or carbenoxolone inhibits 11β-HSD2 and produces identical biochemistry: high BP, hypokalemia, metabolic alkalosis, and low renin/aldosterone. Stopping the trigger reverses the problem. PubMed Central+2Canadian Medical Association Journal+2

4) Transient neonatal AME physiology. In some premature infants, renal 11β-HSD2 activity is immature, so features can resemble AME transiently; careful follow-up is needed to distinguish transient physiology from genetic disease. (Mechanism and enzyme maturation are discussed across reviews of 11β-HSD2 physiology.) Physiology Journals

Causes

Important note: “Causes” of true AME are (A) genetic defects in HSD11B2 or (B) acquired inhibition of 11β-HSD2 (e.g., licorice). However, many disorders create an AME-like (pseudohyperaldosteronism) picture. Below are 20 clearly described causes, with the first group being true AME causes and the remainder being AME-like mimics that present similarly (low renin, hypokalemia, hypertension) and must be ruled out.

True AME causes (HSD11B2 defect or inhibition)

1. Biallelic HSD11B2 pathogenic variants (classic AME). Autosomal recessive. PubMed+1

2. Compound heterozygous HSD11B2 variants (two different mutations). PNAS

3. Promoter/regulatory HSD11B2 defects lowering enzyme expression. (Documented across genetic/structural AME series.) PNAS

4. Non-classic/partial HSD11B2 deficiency (late-onset, milder). AHA Journals

5. Licorice (glycyrrhetinic acid) ingestion—teas, candies, supplements. PubMed Central+1

6. Carbenoxolone exposure, a pharmacologic 11β-HSD inhibitor. Oxford Academic

7. High-dose licorice derivatives in herbal preparations, sometimes unrecognized in “natural” products. Frontiers

8. Potential food/supplement contamination with glycyrrhizin, producing inadvertent exposure patterns. (Epidemiology discussed in licorice risk reviews.) Frontiers

AME-like mimics (pseudohyperaldosteronism to differentiate)

1. Liddle syndrome (ENaC overactivity) causes low-renin, low-aldosterone hypertension with hypokalemia; it mimics AME but enzyme is normal. (Included within pseudohyperaldosteronism frameworks.) Orpha
2. Mineralocorticoid receptor (MR) activating mutations (gain-of-function NR3C2). Presents like AME, often worsened in pregnancy. Orpha
3. Cushing syndrome/ectopic ACTH (massive cortisol can overwhelm 11β-HSD2, activating MR). PubMed
4. 11β-hydroxylase (CYP11B1) deficiency (excess deoxycorticosterone—DOC—acts like a mineralocorticoid). Orpha
5. 17α-hydroxylase/17,20-lyase (CYP17A1) deficiency (also DOC excess). Orpha
6. Apparent “partial 11β-HSD2 deficiency” in essential hypertension (intermediate phenotype reported in adults). AHA Journals
7. Exogenous mineralocorticoids (fludrocortisone) or adrenal steroids with MR activity. Orpha
8. Severe obstructive sleep apnea or chronic stress glucocorticoid excess (functionally boosts MR activation; needs biochemical confirmation). Physiology Journals
9. Congenital adrenal enzyme defects producing mineralocorticoid precursors beyond items 12–13 (rare variants; considered in the differential). Orpha
10. Renal parenchymal disease with sodium retention that phenocopies low-renin hypertension (distinguished by labs and imaging). Orpha
11. Chronic licorice beverages (e.g., teas) in large amounts, often missed in history-taking. PubMed
12. Certain topical/herbal products containing licorice extracts, enough to alter electrolytes in sensitive individuals. (Case-based risk discussions.) Frontiers

Symptoms and signs

1. High blood pressure (often early and severe). This is the main feature and can appear in infancy/childhood; it may be resistant to usual doses of common drugs. Orpha+1

2. Low potassium (hypokalemia). Causes fatigue, muscle cramps, and can trigger heart rhythm changes. PubMed

3. Metabolic alkalosis. The blood becomes more alkaline because of kidney potassium and hydrogen loss driven by MR activation. PubMed

4. Low renin and low aldosterone on labs. Despite “salt-retaining” signs, aldosterone is not high (key clue to AME). PubMed

5. Headaches. Often from high blood pressure. Orpha

6. Muscle weakness or paralysis episodes. Due to low potassium. PubMed

7. Excess thirst and urination (polydipsia/polyuria). Salt handling changes and low potassium reduce urine concentrating ability. preventiongenetics.com

8. Poor weight gain/failure to thrive in infants. Hypertension and electrolyte problems impair growth. preventiongenetics.com

9. Short stature or slow growth over time. Chronic biochemical stress can blunt growth. preventiongenetics.com

10. Irritability or lethargy. Non-specific signs from electrolytes and BP swings. Orpha

11. Constipation. Can occur with hypokalemia. PubMed

12. Cardiac palpitations/arrhythmias. Low potassium alters heart rhythm; ECG may show U-waves. PubMed

13. No edema, or only mild edema. Volume expansion is present but not always obvious as swelling. UpToDate

14. Possible nephrocalcinosis or kidney issues over time. Long-standing hypokalemia and hypertension can hurt kidneys. Orpha

15. Family history of early severe hypertension (when genetic). Look for autosomal recessive patterns (affected siblings). PNAS

Diagnostic tests

Below, tests are grouped exactly as requested.

A) Physical examination (at the bedside)

1. Accurate blood pressure in both arms (right cuff size, repeated on separate days). Persistent hypertension is the first red flag. Orpha

2. Growth assessment (weight, length/height, growth velocity, head circumference in infants). AME can impair growth. preventiongenetics.com

3. Hydration and edema check (mucosa, skin turgor, ankle/eyelid swelling). Volume status helps interpret renin/aldosterone. UpToDate

4. Neuromuscular exam for weakness or cramps suggesting hypokalemia. PubMed

5. Fundoscopy for hypertensive retinopathy in severe/long-standing cases. UpToDate

B) “Manual”/bedside maneuvers and monitoring

6. Repeated standardized BP measurements (seated, after rest) to confirm true hypertension and exclude “white-coat” effects. UpToDate

7. Ambulatory blood pressure monitoring (ABPM) to document 24-hour load and nocturnal pattern. Useful in resistant pediatric hypertension. UpToDate

8. Orthostatic BP/HR testing to screen for secondary contributors and volume status shifts (supportive, not diagnostic). UpToDate

9. Dietary review focused on licorice/herbal intake (teas, candies, supplements). This is a “manual” history task but crucial for acquired AME. Canadian Medical Association Journal

10. Family screening BP checks (siblings, parents) when genetic AME is suspected. PNAS

C) Laboratory and pathological testing

11. Serum electrolytes and acid–base (expect hypokalemia and metabolic alkalosis). PubMed

12. Plasma renin activity (or direct renin) and aldosterone (both typically low in AME). PubMed

13. Urinary cortisol-to-cortisone metabolite ratios (e.g., (THF+allo-THF)/THE). Ratios are high in AME because 11β-HSD2 is weak. PubMed

14. 24-hour urinary free cortisol and cortisone (high cortisol/cortisone ratio supports AME). PubMed

15. Genetic testing of HSD11B2 to confirm pathogenic variants (the gold standard for inherited AME). Orpha+1

16. Kidney function tests and urinalysis (assess damage or nephrocalcinosis risk). Orpha

17. ACTH and cortisol profile if Cushing syndrome is a concern (to distinguish cortisol excess overwhelming 11β-HSD2). PubMed

D) Electrodiagnostic testing

18. 12-lead ECG to look for hypokalemia effects (U-waves, prolonged QT, arrhythmias). This guides urgency and potassium repletion. PubMed

19. Echocardiography (not “electro” but a cardiology test) to assess left-ventricular hypertrophy from longstanding hypertension. (Common in resistant pediatric HTN pathways.) UpToDate

E) Imaging and specialized studies

20. Renal ultrasound (± Doppler) to check kidney size/structure and exclude other secondary hypertension causes; adrenal imaging is considered when enzyme defects producing DOC excess are suspected. UpToDate

Non-pharmacological treatments

1. Strict salt restriction: Eat a low-sodium diet (target ~1,500–2,000 mg/day unless your clinician sets another goal). This directly lowers blood pressure in salt-sensitive states like AME because the kidney’s MR is over-signaled by cortisol; less sodium in equals less water retention. Purpose: reduce hypertension and protect heart/kidney. Mechanism: decreased extracellular volume and MR-driven sodium reabsorption. PubMed Central

2. Absolutely avoid licorice (and products with glycyrrhizin, glycyrrhetinic acid, or carbenoxolone): even “natural” candies/teas can raise BP and lower potassium by blocking 11β-HSD2. Purpose: remove a powerful AME mimic. Mechanism: stops enzyme inhibition so cortisol no longer acts like aldosterone in the kidney. MDPI+1

3. DASH-style eating pattern with potassium-rich foods (as allowed by labs): fruits, vegetables, legumes, and whole grains support blood-pressure control; potassium helps counter renal sodium retention and may ease hypokalemia. Always individualize if kidney function is reduced. Purpose: BP control, electrolyte support. Mechanism: higher potassium intake (when safe), reduced sodium density, vascular benefits. Frontiers

4. Label reading and salt-swap skills: learn common high-sodium foods (instant noodles, chips, sauces, pickles) and use herbs, acids (lemon/vinegar), and salt-free spice mixes instead. Purpose: sustain low sodium long-term. Mechanism: behavior change reduces daily sodium burden. Frontiers

5. Fluid balance and hydration: steady fluid intake prevents volume swings and helps potassium management. Purpose: BP stability and symptom control. Mechanism: moderates RAAS-independent volume changes in a salt-sensitive kidney. Frontiers

6. Home BP monitoring: measure BP at the same times daily and after major diet changes; share logs with your clinician. Purpose: detect patterns and guide therapy. Mechanism: early feedback loop for salt and medication adjustments. Frontiers

7. Medication and supplement review: remove hidden licorice, carbenoxolone, or other 11β-HSD2 inhibitors. Purpose: avoid pseudo-AME triggers. Mechanism: stops enzyme inhibition. MDPI

8. Weight management if overweight: modest weight loss helps blood pressure in most people and reduces dose needs. Purpose: BP control. Mechanism: lowers sympathetic tone and improves vascular function. Frontiers

9. Regular aerobic activity (as advised): walking, cycling, or swimming most days helps BP. Purpose: cardiovascular health. Mechanism: improved endothelial function, reduced vascular resistance. Frontiers

10. Sleep hygiene and screen for sleep apnea if snoring/daytime sleepiness: untreated sleep apnea worsens BP. Purpose: lower overall BP burden. Mechanism: reduces nocturnal sympathetic surges. Frontiers

11. Stress reduction (breathing, mindfulness): helpful adjunct to lower sympathetic drive. Purpose: small BP reductions and quality of life. Mechanism: lowers catecholamine surges. Frontiers

12. Potassium-aware food plan with clinician: use foods naturally high in potassium when serum levels are low and kidneys are healthy; avoid excess if kidney function falls. Purpose: correct hypokalemia safely. Mechanism: dietary potassium entry offsets renal potassium loss. PubMed Central

13. Limit alcohol and stop tobacco: both raise BP and harm vessels. Purpose: reduce cardiovascular risk. Mechanism: improves autonomic and vascular function. Frontiers

14. Family and genetic counseling: explain autosomal recessive inheritance; offer testing to siblings/parents and counseling before pregnancy. Purpose: prevention and early detection. Mechanism: identifies carriers and affected individuals earlier. PubMed Central

15. Pregnancy planning: coordinate with obstetrics and nephrology; avoid licorice; choose pregnancy-safer BP drugs. Purpose: protect mother and fetus. Mechanism: tailored therapy in a high-risk physiologic state. PubMed Central

16. Pediatric growth and development support: monitor nutrition and growth charts closely. Purpose: optimize growth in affected children. Mechanism: early nutrition + BP control improves outcomes. preventiongenetics.com

17. Limit NSAIDs unless essential: some NSAIDs raise BP and worsen kidney perfusion. Purpose: protect kidneys and BP control. Mechanism: prostaglandin inhibition can increase sodium retention. Frontiers

18. Electrolyte action plan: have a plan for cramps or palpitations; know when to recheck potassium. Purpose: prevent complications of hypokalemia. Mechanism: early correction prevents arrhythmia. PubMed Central

19. Vaccinations and infection control: severe vomiting/diarrhea can drop potassium further; staying well reduces swings. Purpose: maintain electrolyte stability. Mechanism: fewer acute losses. Frontiers

20. Education on lifelong management: AME is chronic; consistent low-sodium eating and trigger avoidance are essential even when you feel well. Purpose: long-term BP and kidney protection. Mechanism: sustained reduction in salt-driven MR activation. PubMed Central

---

Drug treatments

Always individualize doses with your clinician, especially in children, pregnancy, or kidney disease. “Time” below means common once-daily vs twice-daily patterns; exact timing varies by brand and age.

1. Amiloride (K-sparing diuretic; ENaC blocker)
   What it does: First-line in AME because it blocks the epithelial sodium channel (ENaC) in the kidney’s collecting duct, the final step by which MR signaling retains sodium and wastes potassium. Purpose: Lower BP and correct hypokalemia. Dose/time: Often 5–10 mg once or twice daily (adult ranges); pediatric doses are weight-based. Mechanism: Direct ENaC blockade reduces sodium reabsorption and potassium loss, counteracting cortisol-driven MR effects even when aldosterone is low. Side effects: High potassium if over-corrected, nausea, dizziness; caution in reduced kidney function. Evidence supports ENaC blockers as pathophysiology-targeted therapy in AME. PubMed Central

2. Triamterene (K-sparing diuretic; ENaC blocker)
   Similar role to amiloride when amiloride is unavailable. Purpose: BP control and potassium preservation. Dose/time: Common adult dose 50–100 mg twice daily (often co-formulated). Mechanism: ENaC inhibition blunts sodium reuptake in the cortical collecting duct. Side effects: Hyperkalemia risk, kidney stones (rare), dizziness. Used as an alternative ENaC blocker in salt-sensitive states like AME. PubMed Central

3. Eplerenone (MR antagonist; “selective”)
   What it does: Blocks the mineralocorticoid receptor that cortisol is wrongly activating in AME. Purpose: Lower BP and spare potassium. Dose/time: Often 25–50 mg once or twice daily, titrated. Mechanism: Competitive MR blockade reduces gene transcription for ENaC and Na⁺/K⁺ handling. Side effects: Hyperkalemia, creatinine rise; fewer anti-androgen effects than spironolactone. Often preferred when gynecomastia risk is a concern. PubMed Central

4. Spironolactone (MR antagonist; “non-selective”)
   What it does: Another MR blocker that reduces salt retention and potassium loss. Purpose: BP lowering and potassium correction. Dose/time: 25–100 mg once daily (adults), lower in children. Mechanism: Antagonizes MR-mediated gene effects on ENaC and sodium transport. Side effects: Hyperkalemia, breast tenderness/gynecomastia, menstrual irregularities. Effective, widely available, and often used with ENaC blockers for additive benefit. PubMed Central

5. Hydrochlorothiazide or Chlorthalidone (thiazide diuretics)
   What they do: Reduce sodium reabsorption earlier in the nephron, lowering blood volume and BP. Purpose: Adjunct for BP control if MR blockade/ENaC block is insufficient. Dose/time: HCTZ 12.5–25 mg daily; chlorthalidone 12.5–25 mg daily. Mechanism: Inhibit NCC in the distal tubule; may worsen potassium loss, so pair with K-sparing agents. Side effects: Low potassium, low sodium, photosensitivity, gout flare. Useful add-on in resistant monogenic hypertension. Frontiers

6. Amlodipine (dihydropyridine calcium-channel blocker)
   What it does: Relaxes arteries to lower BP. Purpose: Add-on for BP control when diuretic/MR strategies need help. Dose/time: 5–10 mg once daily. Mechanism: Inhibits L-type calcium channels in vascular smooth muscle. Side effects: Ankle swelling, flushing, headache. Neutral for potassium balance. Frontiers

7. Lisinopril (ACE inhibitor)
   What it does: Lowers angiotensin II; often less potent in low-renin states like AME but still useful for heart/kidney protection. Purpose: Add-on for BP and organ protection. Dose/time: 5–20 mg once daily. Mechanism: Blocks ACE → lowers ATII → vasodilation; can raise potassium slightly. Side effects: Cough, high potassium, kidney function changes, rare angioedema. Frontiers

8. Losartan (ARB)
   What it does: Blocks angiotensin II type-1 receptors; like ACEi, benefit is mainly vasodilation and organ protection. Purpose: Add-on in resistant cases. Dose/time: 50–100 mg once daily. Mechanism: AT1R blockade reduces vasoconstriction and aldosterone drive (aldosterone already low in AME). Side effects: High potassium, dizziness. Frontiers

9. Dexamethasone (glucocorticoid “ACTH suppression test/therapy in severe AME”)
   What it does: In select severe cases, a low dose can reduce cortisol production by lowering ACTH drive, thereby reducing MR overstimulation by cortisol. Purpose: Pathway-targeted therapy when MR/ENaC blockade and diet are not enough. Dose/time: Very individualized; specialist use only. Mechanism: Negative feedback on HPA axis to cut endogenous cortisol load. Side effects: Cushingoid effects, glucose elevation, infection risk, growth effects in children—so used cautiously. PubMed Central

10. Potassium chloride (oral supplement)
    What it does: Repletes potassium to normal levels to prevent cramps and arrhythmias. Purpose: Correct hypokalemia quickly. Dose/time: Individualized by labs; often divided doses with food. Mechanism: Restores serum K⁺ while other therapies reduce urinary losses. Side effects: GI upset; dangerous if kidney function is poor or if combined with too many K-sparing drugs—close monitoring required. PubMed Central

11. Magnesium supplementation (if low)
    What it does: Corrects magnesium deficiency that can worsen potassium loss and arrhythmia risk. Purpose: Support potassium stability and muscle/heart function. Dose/time: Product-dependent. Mechanism: Magnesium is a cofactor in potassium handling and cardiac conduction. Side effects: Diarrhea; caution in renal impairment. Frontiers

12. Beta-blocker (e.g., metoprolol)
    What it does: Slows heart rate and lowers BP; useful if tachycardia or angina present. Purpose: Adjunct BP/heart-rate control. Dose/time: e.g., metoprolol 25–100 mg/day in divided doses/ER forms. Mechanism: β1 blockade reduces cardiac output and renin (renin already low in AME, so effect is mainly cardiac). Side effects: Fatigue, cold extremities, sleep changes. Frontiers

13. Central alpha-2 agonist (e.g., clonidine)
    What it does: Lowers sympathetic outflow. Purpose: Rescue add-on for severe resistant BP while path-targeted drugs are optimized. Dose/time: e.g., 0.1–0.3 mg/day divided or patch. Mechanism: Brainstem α2 stimulation reduces norepinephrine release. Side effects: Dry mouth, sedation, rebound hypertension if abruptly stopped. Frontiers

14. Hydralazine
    What it does: Direct arteriolar dilator for difficult hypertension. Purpose: Bridge therapy in resistant cases. Dose/time: e.g., 25–50 mg 2–3 times daily. Mechanism: Smooth-muscle relaxation via unclear nitric-oxide related pathways. Side effects: Headache, edema, tachycardia, rare lupus-like syndrome. Frontiers

15. Nifedipine (long-acting)
    Alternative to amlodipine for vasodilation. Purpose: BP lowering. Dose/time: e.g., 30–60 mg once daily (ER). Mechanism: L-type calcium channel block. Side effects: Flushing, edema, headache. Frontiers

16. Indapamide (thiazide-like diuretic)
    What it does: Long-acting diuretic that lowers BP; watch potassium. Purpose: Add-on for BP. Dose/time: 1.25–2.5 mg once daily. Mechanism: Distal tubular sodium-chloride cotransporter inhibition. Side effects: Hypokalemia, hyponatremia. Use with K-sparing agent in AME. Frontiers

17. Minoxidil
    What it does: Potent vasodilator for refractory cases under specialist care. Purpose: Last-line BP control. Dose/time: Small starting doses with diuretic and beta-blocker. Mechanism: Opens potassium channels in vascular smooth muscle. Side effects: Fluid retention, tachycardia, hypertrichosis. Frontiers

18. Torsemide (loop diuretic) – selected cases
    What it does: Loop diuretic for edema or advanced kidney disease; can worsen potassium loss so combine with K-sparing therapy. Purpose: Volume control. Dose/time: individualized. Mechanism: Blocks NKCC2 in the loop of Henle. Side effects: Hypokalemia, dehydration. Frontiers

19. Eplerenone + Amiloride combination
    What it does: Targets both MR and ENaC for stronger path-based control. Purpose: Better BP and potassium stability than either alone in some patients. Dose/time: individualized dual regimen. Mechanism: Dual blockade of MR signaling and final sodium entry step. Side effects: Hyperkalemia—requires frequent labs. PubMed Central

20. Low-dose Aspirin (selected high-risk adults only, not routine for children)
    What it does: Cardiovascular risk reduction in chosen patients per general guidelines. Purpose: Secondary prevention if atherosclerotic risk is high. Dose/time: e.g., 75–100 mg daily when indicated. Mechanism: Antiplatelet. Side effects: Bleeding, GI upset. Decision is individualized and not AME-specific. Frontiers

---

Dietary molecular supplements

Important: Supplements are adjuncts only. None treat AME itself. Discuss all supplements with your clinician, especially if you have kidney disease or take potassium-sparing medicines.

1. Potassium citrate (when potassium is low and kidney function is adequate)
   Role: Repletes potassium and may correct mild metabolic alkalosis by providing citrate, which the body converts to bicarbonate carefully. Dose: individualized; often divided doses with meals. Function/mechanism: raises serum potassium, counters renal potassium wasting driven by MR signaling; citrate can reduce calcium stone risk in high-risk patients. Caution: hyperkalemia if combined with strong K-sparing therapy or low GFR. PubMed Central

2. Magnesium (e.g., magnesium glycinate)
   Role: Supports neuromuscular stability and heart rhythm; low magnesium can make potassium repletion harder. Dose: product-dependent. Mechanism: improves renal potassium handling and stabilizes cardiac conduction. Caution: diarrhea; dose-adjust in CKD. Frontiers

3. Omega-3 fatty acids (EPA/DHA)
   Role: Small additive BP reductions and cardiovascular risk support. Dose: commonly 1–2 g/day of combined EPA+DHA (check label). Mechanism: anti-inflammatory, endothelial effects, slight vasodilation. Caution: bleeding risk when combined with antiplatelets/anticoagulants. Frontiers

4. Coenzyme Q10
   Role: Modest BP support in some studies and mitochondrial aid. Dose: 100–200 mg/day. Mechanism: antioxidant/mitochondrial cofactor; may improve endothelial nitric oxide. Caution: variable evidence; not a substitute for core therapy. Frontiers

5. Vitamin D (if deficient)
   Role: Corrects deficiency; general cardiovascular and bone health. Dose: per level (e.g., 800–2,000 IU/day maintenance). Mechanism: endocrine/immune modulation; BP effects are inconsistent. Caution: avoid excessive dosing. Frontiers

6. Beetroot (dietary nitrate) or nitrate-rich greens
   Role: Small, short-term BP lowering via nitric-oxide pathway. Dose: food-based (e.g., 250–500 ml juice) or cooked greens. Mechanism: nitrate → nitrite → NO-mediated vasodilation. Caution: interacts with some drugs; watch potassium content in CKD. Frontiers

7. Garlic preparations
   Role: Modest BP effects in some meta-analyses. Dose: varies by standardized product. Mechanism: vasodilatory sulfur compounds may improve endothelial function. Caution: odor, GI upset, bleeding risk with anticoagulants. Frontiers

8. Cocoa flavanols (unsweetened cocoa)
   Role: Small BP benefits via endothelial nitric oxide. Dose: product-dependent flavanol content. Mechanism: improved endothelial function. Caution: added sugars in commercial chocolates counteract benefits. Frontiers

9. Probiotics (selected strains)
   Role: Minor BP effects in some trials; gut-metabolite modulation. Dose: per label. Mechanism: reduced gut-derived vasoconstrictive metabolites; improved endothelial tone (hypothesized). Caution: variable quality; benefits are small. Frontiers

10. Plant-based diet emphasis (as a “supplement strategy”)
    Role: Increases potassium, magnesium, and fiber from whole foods to support BP control. Dose: daily pattern. Mechanism: improves sodium–potassium ratio, vascular health. Caution: monitor potassium if GFR declines. Frontiers

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune-booster, regenerative, or stem-cell drugs that treat or reverse AME. AME is a kidney enzyme deficiency in salt handling, not an immune disease or a tissue-loss disorder suitable for stem-cell replacement therapy at this time. The safest, evidence-based approach is dietary sodium restriction, avoidance of licorice-like inhibitors, and targeted drugs that block MR/ENaC or lower blood pressure. Any claims of stem-cell or “regenerative” cures for AME should be viewed skeptically. PubMed Central

• Note 1–6 (combined): Current research and reviews of monogenic hypertension and HSD11B2 deficiency do not support immune or stem-cell drug use in AME. Management is medical and supportive; transplantation is reserved for end-stage kidney disease, not to fix the enzyme defect. Oxford Academic+1

---

Procedures / Surgeries

1. Renal transplantation (for end-stage kidney disease caused by long-standing hypertension): AME itself is managed medically, but if kidneys fail, transplant restores kidney function and helps BP control. It does not “cure” the gene defect elsewhere, but kidney salt handling normalizes. Why done: treat kidney failure and protect life/quality of life. PubMed Central

2. Arteriovenous fistula creation (for hemodialysis access if ESRD occurs): a surgical access to allow chronic dialysis. Why done: life-sustaining dialysis while awaiting transplant or if transplant is not an option. Frontiers

3. Peritoneal dialysis catheter placement (for home dialysis in ESRD): a peritoneal catheter is placed surgically. Why done: provide an alternative to hemodialysis when transplant is not immediate. Frontiers

4. Catheter-based renal denervation (selected adult resistant hypertension cases): not AME-specific and evidence is evolving; may be considered only after expert review when medications and diet fail. Why done: reduce renal sympathetic tone to aid BP control. Frontiers

5. Implantable loop recorder (if recurrent arrhythmias from severe hypokalemia are suspected): not a treatment for AME, but helps diagnose dangerous rhythm problems. Why done: guide arrhythmia management. Frontiers

---

Prevention tips

1. Know your diagnosis and share it with all clinicians. Early recognition prevents years of uncontrolled BP. PubMed Central

2. Keep sodium low every day; learn food labels and common salt traps. PubMed Central

3. Avoid licorice and carbenoxolone in any form. Check candies, lozenges, teas, and “herbal” mixes. MDPI

4. Do not stop MR/ENaC medicines abruptly; monitor potassium regularly. PubMed Central

5. Review all new medicines/supplements with your clinician for 11β-HSD2 effects. MDPI

6. Home BP checks with a log for your clinic visits. Frontiers

7. Healthy weight, daily movement, good sleep. Frontiers

8. Plan pregnancies early with specialists; avoid licorice and unsafe BP drugs. PubMed Central

9. Family screening and genetic counseling for siblings/relatives. PubMed Central

10. Regular heart and kidney follow-up (labs, ECG/echo, urinalysis). PubMed Central

---

When to see a doctor

• Now/urgent: severe headache, chest pain, shortness of breath, fainting, palpitations, severe weakness or paralysis, or very high BP (e.g., ≥180/120 mmHg) — these can signal hypertensive emergency or dangerous hypokalemia. PubMed Central

• Soon: new muscle cramps, new edema, dizziness, persistent BP above your target, or any licorice exposure with rising BP. MDPI

• Routine: regular visits for BP review, potassium checks, kidney function tests, and medication/diet check-ins. PubMed Central

---

What to eat and what to avoid

1. Eat fresh fruits/vegetables, legumes, and whole grains (supports potassium and BP). Avoid heavily processed, salty foods (instant noodles, chips, pickles). Frontiers

2. Eat home-cooked meals with herbs, citrus, garlic for flavor. Avoid adding table salt or salty sauces. Frontiers

3. Drink water regularly. Avoid salty broths/soups. Frontiers

4. Include potassium-rich foods if labs allow (bananas, oranges, spinach, lentils). Avoid sudden high-potassium binges if you have CKD or take multiple K-sparing drugs. PubMed Central

5. Use unsalted nuts/seeds. Avoid salted snacks. Frontiers

6. Try low-sodium bread and low-salt dairy. Avoid regular processed cheeses and salty breads. Frontiers

7. Choose fresh meats/fish. Avoid cured meats (sausages, bacon, deli meats). Frontiers

8. Enjoy nitrate-rich greens and beets (in moderation). Avoid sugary beverages and energy drinks that can raise BP. Frontiers

9. Check herbal teas/lozenges for licorice. Avoid any product listing licorice/glycyrrhizin. MDPI

10. Limit alcohol; avoid tobacco. Frontiers

---

Frequently asked questions

1. Is AME the same as hyperaldosteronism?
   No. It looks similar but aldosterone is low in AME. Cortisol wrongly activates the mineralocorticoid receptor because 11β-HSD2 is weak. PubMed Central

2. How rare is AME?
   Extremely rare. Only small numbers of families are reported worldwide. Some groups with more consanguinity report more cases. Frontiers

3. What test proves AME?
   A high urine cortisol-to-cortisone metabolite ratio supports the diagnosis, and HSD11B2 genetic testing confirms it. eymj.org+1

4. Can diet alone fix AME?
   Diet helps a lot (especially low sodium and no licorice), but most people also need MR/ENaC-targeted medicines. PubMed Central

5. Why are ENaC blockers so helpful?
   They shut the final sodium entry channel that MR signaling turns on, directly opposing the main problem in AME. PubMed Central

6. Is spironolactone safe?
   It’s effective but can cause high potassium and hormonal side effects; eplerenone has fewer hormonal effects. Labs should be checked regularly. PubMed Central

7. Can I use ACE inhibitors or ARBs?
   Yes, as add-ons for BP and organ protection, though AME is low-renin, so the main benefit is vasodilation and kidney/heart protection. Frontiers

8. Is there a cure?
   There’s no gene cure yet. Consistent salt restriction, avoiding licorice, and right medicines usually control BP well. Kidney transplant treats kidney failure if it occurs, not the gene defect itself. PubMed Central

9. Can children with AME live normal lives?
   With early diagnosis, good diet, and targeted therapy, many children grow and live well. Regular follow-up is essential. preventiongenetics.com

10. Is licorice in toothpaste or candy a big deal?
    Even small daily amounts can matter. Check labels and avoid glycyrrhizin/glycyrrhetinic acid. MDPI

11. Does stress cause AME?
    Stress doesn’t cause it, but it can raise BP; stress control helps overall management. Frontiers

12. Can pregnancy worsen AME?
    Pregnancy changes blood volume and BP; close obstetric-nephrology care is needed, with safe drug choices and strict licorice avoidance. PubMed Central

13. Will I always need medicine?
    Most people need ongoing therapy. Doses can change with growth, weight, and kidney function. PubMed Central

14. Is genetic testing necessary for family members?
    It’s very helpful to find carriers and detect affected siblings early. PubMed Central

15. What is the long-term outlook?
    With early, steady control of BP and potassium, the outlook is much better, and the risk of heart and kidney damage is reduced. PubMed Central

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 21, 2025.